In December 2011, Chi-Med entered into a global licensing, co-development, and commercialisation agreement regarding its highly selective c-Met inhibitor savolitinib with AstraZeneca.
Development costs for savolitinib in China are shared between Chi-Med and AstraZeneca, with Chi-Med continuing to lead the development in China. AstraZeneca leads and pays for the development of savolitinib for the rest of the world.
Chi-Med was entitled to receive an upfront payment as well as further payments contingent on the successful achievement of clinical development and first sale milestones.
The agreement also contains possible future commercial sale milestones, a fixed royalty of on all sales in China and double-digit tiered royalties on all sales made outside of China.
In October 2013, Chi-Med entered into a licensing, co-development and commercialisation agreement in China with Lilly for fruquintinib, a selective inhibitor of the vascular endothelial growth factor receptor tyrosine kinase.
Under the terms of the agreement, the costs of future development of fruquintinib in China, to be carried out by Chi-Med, will be shared between Chi-Med and Lilly.
Chi-Med has received upfront payments, as well as development and regulatory approval milestone payments. Chi-Med has also been receiving royalty payments since the late-Nov 2018 fruquintinib commercial launch.
Innovent Biologics, a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, autoimmune, metabolic and other major diseases.
It has built up a pipeline of 23 drug assets, led by Tyvyt®(IBI-308, generic name: sintilimab injection), anti-PD-1 monoclonal antibody co-developed with Eli Lilly, which received marketing approval in China for relapsed or refractory classical Hodgkin lymphoma in late 2018.
In late November 2018, we entered into a global collaboration agreement with Innovent Biologics to evaluate the safety, tolerability and efficacy of fruquintinib in combination with their now commercial-stage drug Tyvyt®.
Shanghai Junshi Biosciences is a biopharmaceutical company based in Shanghai, China that focuses on discovering, developing and commercializing innovative drugs.
Junshi has developed a product pipeline comprising 17 drug candidates, covering a wide variety of indications including immuno-oncology, metabolic diseases, inflammation or autoimmune diseases and neurologic diseases.
In late November 2018, we entered into a global collaboration agreement with Junshi to evaluate the safety, tolerability and efficacy of surufatinib in combination with their now commercial-stage drug Tuoyi® (generic name: toripalimab, JS001), a PD-1 monoclonal antibody approved in China for the treatment of melanoma in late 2018.
BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. It is committed to expediting the development of a diverse pipeline of novel therapeutics for cancer.
It currently markets two internally-discovered oncology products: anti-PD-1 antibody tislelizumab in China, and BTK inhibitor BRUKINSA™ (zanubrutinib) in the United States.
In May 2020, we entered into a clinical collaboration agreement to evaluate the safety, tolerability and efficacy of combining two of Chi-Med’s drug candidates, surufatinib and fruquintinib, with BeiGene’s anti-PD-1 antibody tislelizumab, for the treatment of various solid tumor cancers, in the U.S., Europe, China and Australia.